Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1324


Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators.

Pietrasik G, Goldenberg I, McNitt S, Polonsky B, Moss AJ, Zareba W.

J Cardiovasc Electrophysiol. 2009 Apr;20(4):395-400. doi: 10.1111/j.1540-8167.2008.01333.x. Epub 2008 Oct 27.


Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II.

Goldenberg I, Moss AJ, Hall WJ, McNitt S, Zareba W, Andrews ML, Cannom DS; Multicenter Automatic Defibrillator Implantation Trial (MADIT) II Investigators.

Circulation. 2006 Jun 20;113(24):2810-7. Epub 2006 Jun 12.


Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators.

Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B, Arnold JM, Moyé L, Pfeffer M.

J Am Coll Cardiol. 1997 Feb;29(2):229-36.


Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.

Ghali JK, Tam SW, Ferdinand KC, Lindenfeld J, Sabolinski ML, Taylor AL, Worcel M, Curry CL, Cohn JN; A-HeFT Investigators.

Am J Cardiovasc Drugs. 2007;7(5):373-80.


ACE inhibitors in heart failure: what more do we need to know?

Demers C, Mody A, Teo KK, McKelvie RS.

Am J Cardiovasc Drugs. 2005;5(6):351-9. Review.


Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction.

Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, Zareba W, McNitt S, Andrews ML; MADIT-II Investigators.

J Am Coll Cardiol. 2008 Jan 22;51(3):288-96. doi: 10.1016/j.jacc.2007.08.058.


Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).

Ruwald MH, Ruwald AC, Jons C, Alexis J, McNitt S, Zareba W, Moss AJ.

J Am Coll Cardiol. 2013 Apr 9;61(14):1518-26. doi: 10.1016/j.jacc.2013.01.020.


Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II.

Goldenberg I, Gillespie J, Moss AJ, Hall WJ, Klein H, McNitt S, Brown MW, Cygankiewicz I, Zareba W; Executive Committee of the Multicenter Automatic Defibrillator Implantation Trial II.

Circulation. 2010 Sep 28;122(13):1265-71. doi: 10.1161/CIRCULATIONAHA.110.940148. Epub 2010 Sep 13.


Which strategy is "best" after myocardial infarction? The Beta-blocker Strategy plus Implantable Cardioverter Defibrillator Trial: rationale and study design.

Raviele A, Bongiorni MG, Brignole M, Cappato R, Capucci A, Gaita F, Mangiameli S, Montenero A, Pedretti R, Salerno J, Sermasi S.

Am J Cardiol. 1999 Mar 11;83(5B):104D-111D.


Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).

Singh JP, Hall WJ, McNitt S, Wang H, Daubert JP, Zareba W, Ruskin JN, Moss AJ; MADIT-II Investigators.

J Am Coll Cardiol. 2005 Nov 1;46(9):1712-20. Epub 2005 Oct 10.


Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF).

Ghali JK, Piña IL, Gottlieb SS, Deedwania PC, Wikstrand JC; MERIT-HF Study Group.

Circulation. 2002 Apr 2;105(13):1585-91.


Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population).

Zareba W, Piotrowicz K, McNitt S, Moss AJ; MADIT II Investigators.

Am J Cardiol. 2005 Jun 15;95(12):1487-91.


Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease.

Peterson JG, Topol EJ, Sapp SK, Young JB, Lincoff AM, Lauer MS.

Am J Med. 2000 Oct 1;109(5):371-7.


Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.

Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B, Heidenreich PA, Knabel T, Konstam MA, Steimle A, Warner Stevenson L.

J Am Coll Cardiol. 2003 May 7;41(9):1529-38.


[Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry].

Arós F, Loma-Osorio A, Vila J, López-Bescós L, Cuñat J, Rodríguez E, San José JM, Heras M, Marrugat J; Investigadores del PRIAMHO II.

Rev Esp Cardiol. 2006 Apr;59(4):313-20. Spanish.


Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators.

N Engl J Med. 2002 Mar 21;346(12):877-83. Epub 2002 Mar 19.


Failure of benefit and early hazard of bucindolol for Class IV heart failure.

Anderson JL, Krause-Steinrauf H, Goldman S, Clemson BS, Domanski MJ, Hager WD, Murray DR, Mann DL, Massie BM, McNamara DM, Oren R, Rogers WJ; Beta-Blocker Evaluation of Survival Trial (BEST) Investigators.

J Card Fail. 2003 Aug;9(4):266-77.


Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.

Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.

Circulation. 2009 Oct 20;120(16):1577-84. doi: 10.1161/CIRCULATIONAHA.109.853648. Epub 2009 Oct 5.

Supplemental Content

Support Center